Get Involved

Your organization’s ARM membership grants benefits to all employees worldwide.

Member Forums

Employees of member organizations are invited to join forums to stay updated on key topics impacting CGT and volunteer for leadership opportunities.

APAC Forum

Convenes ARM members with expertise and interest in learning and informing ARM’s Asia Pacific initiatives.

EU Public Affairs Forum

Engages in European-specific issues and topics related to HTA, pricing, reimbursement, market access, and the regulatory framework of ATMPs.

Patient Forum

Convenes ARM members interested in supporting policies that ensure patients have timely access to cell and gene therapies.

Regulatory CMC Forum

Provides commentary on draft CMC guidance in the US and EU and contributes to ARM’s CMC-focused workshops.

Science & Technology Forum

ARM’s international forum for members of all disciplines to learn about innovations in technology and scientific advancement.

US Policy & Advocacy Forum

Addresses issues related to coverage, payment, and coding for CGT products within Congress and US administrative agencies.

US Regulatory Policy Forum

Facilitates information related to FDA policy and related activities, such as workshops, townhalls, and comment opportunities.

How to Join

All ARM members are welcome to participate in any forum of interest. The number of participants from a member organization is not limited. Click here to register.

Advisory Groups

Serve as a leader in the ARM Community. Advisory Groups guide ARM’s policy & strategy initiatives.

Cell Therapy Advisory Group

Provides expert input on emerging trends and challenges affecting cell therapy, including scientific advancements, CMC issues, and reimbursement.

EU Market Access Advisory Group

Addresses European-specific issues and topics related to HTA, pricing, reimbursement, and market access for ATMPs.

EU Gov. Relations Advisory Group

Provides targeted input on legislative and policy developments impacting the ATMP sector. Supports coordination in engagement with EU institutions, working in complement to the EU Leadership Advisory Group.

EU Leadership Advisory Group

Consists of industry leaders who actively contribute to and promote ARM's priorities throughout Europe, offering advice and direction to ARM's advocacy strategy.

EU Regulatory Advisory Group

Coordinates ARM’s European regulatory strategy, aligning stakeholder input to address key region-specific policy issues and engagement with EMA and MHRA.

Gene Therapy Advisory Group

Provides expert input on emerging trends and challenges affecting gene therapy, including scientific advancements, CMC issues, and reimbursement.

Medicaid Policy Advisory Group

Addresses Medicaid-specific issues and topics that affect patient access and reimbursement for cell and gene therapies.

Medicare Policy Advisory Group

Addresses Medicare-specific issues and topics that affect patient access and reimbursement for cell and gene therapies.

Regulatory CMC Advisory Group

Provides commentary on draft CMC guidance in the US and Europe, works to identify outdated CMC guidance, and proactively identifies guidance gaps.

Regulatory CMC Advisory Group

Provides commentary on draft CMC guidance in the US and Europe, works to identify outdated CMC guidance, and proactively identifies guidance gaps.

Tissue Engineering Advisory Group

Provides expert input on emerging trends and challenges affecting tissue engineering, including scientific advancements, CMC issues, and reimbursement.

US Gov. Relations Advisory Group

Provides strategic guidance on ARM’s advocacy strategy and political engagement. Open only to members who reside in or visit DC frequently.

US Regulatory Policy Advisory Group

Oversees the execution of ARM’s U.S. regulatory policy strategy. Aligns industry perspectives to define policy priorities and advance solutions, while guiding engagement with the FDA.

CGT Value Narrative Advisory Group

Creates a transformational value narrative for approved and emerging CGTs to educate policymakers and the public about the impact of these therapies on patients and the healthcare system.

How to Join

Advisory Groups consist of approximately 8-15 subject matter experts. Individuals at ARM member companies must apply for consideration.

Applications are accepted in June and November each year.

Apply Now More Information

Women’s Executive Forum

ARM’s Women’s Executive Forum fosters collaboration, connectivity, and community among women leaders from ARM member organizations. The Forum aims to support current leaders, encourage future trailblazers by modeling the best and brightest, and promote gender diversity in the industry.

Membership is open to any VP-level woman whose company is an active member of ARM.

Contact [email protected] for more information.

Host a GROW Intern

The GROW Internship Program provides crucial, early-career paid summer internship opportunities in the regenerative medicine sector to talented undergraduate and graduate students whose backgrounds and life experiences have shaped their unique perspectives.

The program aims to foster and build a community of future leaders in the sector by focusing on each applicant's personal journey.

Section with Card Therapy

Abecma

Bristol Myers-Squibb & 2seventybio

Abecma is a chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed or refractory multiple myeloma.

Approved for:

The United States, Canada, Japan, and the European Union

Approved for:

R/R multiple myeloma

Abecma

Bristol Myers-Squibb & 2seventybio

Abecma is a chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed or refractory multiple myeloma.

Approved for:

The United States, Canada, Japan, and the European Union

Approved for:

R/R multiple myeloma

Abecma

Bristol Myers-Squibb & 2seventybio

Abecma is a chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed or refractory multiple myeloma.

Approved for:

The United States, Canada, Japan, and the European Union

Approved for:

R/R multiple myeloma

Abecma

Bristol Myers-Squibb & 2seventybio

Abecma is a chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed or refractory multiple myeloma.

Approved for:

The United States, Canada, Japan, and the European Union

Approved for:

R/R multiple myeloma

Get Involved

Member Forums

APAC Forum

EU Public Affairs Forum

Patient Forum

Regulatory CMC Forum

Science & Technology Forum

US Policy & Advocacy Forum

US Regulatory Policy Forum

How to Join

Advisory Groups

Cell Therapy Advisory Group

EU Market Access Advisory Group

EU Gov. Relations Advisory Group

EU Leadership Advisory Group

EU Regulatory Advisory Group

Gene Therapy Advisory Group

Medicaid Policy Advisory Group

Medicare Policy Advisory Group

Regulatory CMC Advisory Group

Regulatory CMC Advisory Group

Tissue Engineering Advisory Group

US Gov. Relations Advisory Group

US Regulatory Policy Advisory Group

CGT Value Narrative Advisory Group

How to Join

Women’s Executive Forum

Host a GROW Intern

Lorem ipsum dolor sit amet, consectetur adipiscing elit

Gene Editing

Cell Therapy

Tissue Therapeutics

Gene Therapy

Section with Card Therapy

Abecma

Abecma

Abecma

Abecma

Stay Informed Subscribe Today